Fluoxetine, a Selective Serotonin Uptake Inhibitor, for the Treatment of Outpatients with Major Depression
- 31 March 1988
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 8 (2) , 112???115-115
- https://doi.org/10.1097/00004714-198804000-00005
Abstract
In a double-blind, placebo-controlled study the authors found that fluoxetine, a potent and selective inhibitor of serotonin reuptake, was an effective antidepressant in moderately depressed, ambulatory outpatients. Typical adverse effects reported by patients treated with fluoxetine included agitation, nausea, fatigue, and insomnia. Compared to imipramine, fluoxetine was associated with fewer complaints of dry mouth, constipation, and dizziness.This publication has 3 references indexed in Scilit:
- Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptorsBiochemical Pharmacology, 1983
- Fluoxetine, a selective serotonin uptake inhibitorClinical Pharmacology & Therapeutics, 1978
- Pharmacologic Effects in Man of a Specific Serotonin-Reuptake InhibitorScience, 1978